CDKN2C Recombinant Monoclonal Antibody

Code: CSB-RA580611A0HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P42773

Target Names

CDKN2C

Alternative Names

Cyclin-dependent kinase 4 inhibitor C (Cyclin-dependent kinase 6 inhibitor) (p18-INK4c) (p18-INK6), CDKN2C, CDKN6

Species Reactivity

Human

Immunogen

A synthesized peptide from human CDKN2C protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

2D11

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Tested Applications

ELISA, FC

Recommended Dilution

Application	Recommended Dilution
FC	1:50-1:200

Protocols

ELISA Protocol Flow Cytometry (FC) Protocol

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Overlay Peak curve showing jurkat cells stained with CSB-RA580611A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

CDKN2C, also known as p18-INK4c, functions as a critical regulator of cell cycle progression by specifically inhibiting cyclin-dependent kinases 4 and 6. This tumor suppressor protein plays an essential role in controlling the G1-to-S phase transition, making it a significant target for researchers investigating cell cycle dysregulation, cancer biology, and cellular senescence mechanisms. Understanding CDKN2C expression patterns and function provides valuable insights into how cells maintain proliferative control and how this control becomes compromised in malignancy.

This recombinant monoclonal antibody, generated against a synthesized peptide derived from human CDKN2C, offers the reproducibility and consistency that demanding experimental workflows require. As a sequence-defined reagent produced through recombinant technology, it eliminates the lot-to-lot variability that can complicate longitudinal studies or multi-site collaborations. The rabbit IgG format, purified by affinity chromatography, ensures high specificity for your target while minimizing background interference.

Validation studies confirm reliable performance in flow cytometry applications, with recommended dilutions ranging from 1:50 to 1:200. Testing in Jurkat cells, a human T lymphocyte line commonly used in cell cycle and apoptosis research, demonstrated clear positive signal separation from isotype control when cells were fixed and permeabilized, indicating effective detection of intracellular CDKN2C. The antibody has also been validated for ELISA, providing flexibility across different experimental platforms.

This antibody serves researchers exploring CDK inhibitor biology, tumor suppressor mechanisms, hematopoietic cell differentiation, and therapeutic strategies targeting cell cycle regulators. Its validated performance in human samples makes it particularly suitable for oncology research and studies examining proliferative disorders.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB.

Gene References into Functions

Low P18 expression is associated with multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors. PMID:29134609
Cycling hypoxia could induce significant changes in CLDN1 and CLDN7 expression in nasopharyngeal cancer cells, indirectly regulation P18 expression and affecting cell invasion/proliferation. PMID:28055967
genetic association studies in population in Houston TX: Data suggest that CDKN2C copy number variations are associated with sporadic medullary thyroid carcinoma; these associations include presence of distant metastasis at presentation and decreased overall survival. PMID:27610696
CDKN2C gene deletion is associated with plasma cell post-transplantation lymphoproliferative disorders. PMID:27750397
Our study suggests that p18 is a limiting factor for the noncanonical HSC differentiation path in lymphoid lineages. PMID:27287689
CDKN2C inactivation contributes to the leukemogenesis in acute promyelocytic leukemia. PMID:27888400
DNA methyltransferase 3A promotes cell proliferation by silencing CDK inhibitor p18INK4C in gastric carcinogenesis PMID:26350239
Data suggest that cell cycle-dependent kinase inhibitors CDKN2C/p18 and CDKN1A/p21 facilitate cell cycle entry/cell proliferation of quiescent adult human pancreatic beta cells in primary culture (from tissues obtained from organ donors). PMID:26740620
Mutations in CDKN2C is associated with sporadic parathyroid adenoma. PMID:24127162
Analysis of B1a lymphocyte phenotypes of p18-deficient C57BL/6 mice finds that p18 is a key regulator of the size of the B1a cell pool. PMID:22896639
up-regulated HULC promotes proliferation of hepatoma cells through suppressing p18 PMID:22685290
Data indicate that the role of CDKN2C in the adverse outcome of cases with hemizygous deletion was less certain. PMID:21994415
results demonstrate for the first time that N-Myc is a downstream target of RET2A signaling, and propose that induction of N-Myc by RET2A is a key step leading to lower p18 levels during MEN2A tumorigenesis PMID:21112821
conclude that E2F proteins and Sp1 play an important role in the control of p18 expression PMID:12077144
Deletions in the CDKN2C locus and hypermethylation in the CDKN2C promoter region play a role in ovarian granulosa cell tumorogenesis. PMID:12203782
p18INK4c may function as a tumor suppressor in Hodgkin lymphoma, and inactivation may contribute to cell cycle deregulation and defective terminal differentiation of the Reed-Sternberg cells. PMID:14645011
protein kinase C promotes human cancer cell growth through downregulation of p18(INK4c) PMID:15107819
p18(INK4C) loss may contribute to medulloblastoma formation in children PMID:16260494
oncogenic RET and loss of p18 cooperate in the multistep tumorigenesis of medullary thyroid carcinoma PMID:18316595
NaBu-mediated p18( INK4C ) regulation played a role in cell cycle arrest and erythroid differentiation in K562 cells. PMID:18642058
deletions of CDKN2C are important in the progression and clinical outcome of myeloma PMID:18829482
P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma PMID:18942719
Purpose was to investigate genetic alterations of CDKN2C gene in 38 pituitary adenomas. The absence of CDKN2C protein was correlated with LOH of the CDKN2C locus on chromosome 1 and with methylation of the CDKN2C promoter. PMID:18973139
The down-regulation of p18(INK4C) expression may contribute to the tumorigenesis of pituitary adenomas. PMID:19401813
p18(INK4C) is a downstream target of GATA3, constrains luminal progenitor cell expansion, and suppresses luminal tumorigenesis in the mammary gland PMID:19411068
Results identified a molecular basis for CDK inhibitors to exert an antitumor effect in p18-deficient cancers and support the clinical use of CDK inhibitors. PMID:19509251